Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 20/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.63 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26618003 | 0.91 | SCN10A (0.66) | SCN10ANR1I2CACNA1C | |
| SCHEMBL26617515 | 0.91 | SCN10A (0.66) | SCN10ANR1I2CACNA1C | |
| SCHEMBL26617546 | 0.91 | SCN10A (0.65) | SCN10ANR1I2CACNA1C | |
| SCHEMBL26617869 | 0.90 | SCN10A (0.65) | SCN10ANR1I2CACNA1C | |
| SCHEMBL26617591 | 0.90 | SCN10A (0.67) | SCN10ANR1I2CACNA1C | |
| SCHEMBL30681942 | 0.90 | SCN10A (0.65) | SCN10ANR1I2CACNA1C | |
| SCHEMBL30681999 | 0.90 | SCN10A (0.67) | SCN10ANR1I2CACNA1C | |
| SCHEMBL30681898 | 0.90 | SCN10A (0.67) | SCN10ANR1I2CACNA1C | |
| SCHEMBL26617700 | 0.90 | SCN10A (0.65) | SCN10ANR1I2CACNA1C | |
| SCHEMBL26617823 | 0.90 | SCN10A (0.67) | SCN10ANR1I2CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115578-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) | 2025-04-10 | — | — | US | disclosed |
| CN-119585247-A | Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain | 赛特温治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4514789-A1 | <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN | SiteOne Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4455130-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | Chengdu Kanghong Pharmaceutical Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115578-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | SCN8A, SCN10A, SCN7A | SCN10A 2/4885NR1I2 1204/4885CACNA1C 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.